General Pharmacokinetic Model for Drugs Exhibiting Target-Mediated Drug Disposition
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Drugs that bind with high affinity and to a significant extent (relative to dose) to a pharmacologic target such as an enzyme, receptor, or transporter may exhibit nonlinear pharmacokinetic (PK) behavior. Processes such as receptor-mediated endocytosis may result in drug elimination. A general PK model for characterizing such behavior is described and explored through computer simulations and applications to several therapeutic agents. Simulations show that model predicted plasma concentration vs. time profiles are expected to be polyexponential with steeper distribution phases for lower doses and similar terminal disposition phases. Noncompartmental parameters always show apparent Vss and CL(D) decreasing with dose, but apparent clearance decreases only when the binding process produces drug elimination. The proposed model well captured the time-course of drug concentrations for the aldose reductase inhibitor imirestat, the endothelin receptor antagonist bosentan, and recombinant human interferon-beta 1a. This type of model has a mechanistic basis and considerable utility for fully describing the kinetics for various doses of relevant drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“More importantly, target-mediated drug disposition (TMDD) introduces a saturable, dose- and concentration-dependent component of clearance that no power-law regression can capture.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“At low concentrations, target-mediated clearance can dominate; at high concentrations, the target is saturated and linear, FcRn-mediated elimination dominates [47,50].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“A practical constraint in biologics first-in-human modelling is that not all of these disposition parameters can be identified simultaneously. FcRn-mediated linear clearance and central volume of distribution generally scale reliably from non-human primate data and can be estimated with reasonable confidence, whereas TMDD parameters such as target baseline concentration, target turnover, and”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
In the citing paper
“For biologics in particular, this also recognizes that not all parameters are simultaneously identifiable: FcRn-mediated linear clearance and central volume can be carried from non-human primate data, whereas poorly identifiable TMDD parameters are fixed to in vitro or literature values rather than estimated [50,51] (Section 4.5).”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [50]
Citations
Cites
Gibaldi, M., & Perrier, D. (1982) · CRC Press eBooks · doi:10.1201/b14095 · Cited by 4,093
Noseworthy, J. H., Lucchinetti, C., Rodriguez, M., & Weinshenker, B. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431307 · Cited by 2,899
Pestka, S., Langer, J. A., Zoon, K. C., & Samuel, C. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003455 · Cited by 1,825
Protein Sorting by Transport Vesicles
Rothman, J. E., & Wieland, F. T. (1996) · Science · doi:10.1126/science.272.5259.227 · Cited by 1,153
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Comparison of four basic models of indirect pharmacodynamic responses
Dayneka, N. L., Garg, V., & Jusko, W. J. (1993) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01061691 · Cited by 821
Self-citationClozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Recycling receptors: the round-trip itinerary of migrant membrane proteins
Brown, M. S., Anderson, R. G. W., & Goldstein, J. L. (1983) · Cell · doi:10.1016/0092-8674(83)90052-1 · Cited by 587
Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganó, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553
Phase I study of recombinant tumor necrosis factor in cancer patients.
Blick, M. B., Sherwin, S. A., Rosenblum, M. G., & Gutterman, J. U. (1987) · PubMed · Cited by 426
Research works printed but not linked: 3
- D. Z. D'Argenio and A. Schumitzky. ADAPT II user's guide. Biomedical Simulations Resource, Los Angeles (1997).
- W. J. Jusko. Guidelines for collection and analysis of pharmacokinetic data. In W. E. Evans, J. J. Schentag, and W. J. Jusko (eds.), Applied Pharmacokinetics, Applied Therapeutics, Inc., Vancouver, 1992, Ch. 2.
- J. G. Wagner. A new generalized nonlinear pharmacokinetic model and its implications. In J. G. Wagner (ed.), Biopharmaceutics and Relevant Pharmacokinetics, Drug Intelligence Publications, Hamilton, 1971, pp. 302–317.
Cited by
Items 401–500 of 612
Conner, K. P., Pastuskovas, C. V., Soto, M., Thomas, V. A., Wagner, M., & Rock, D. A. (2020) · mAbs · doi:10.1080/19420862.2020.1746520 · Cited by 7
Target-mediated exposure enhancement: a previously unexplored limit of TMDD
Glassman, P. M., & Muzykantov, V. R. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09693-1 · Cited by 7
Sauteur-Robitaille, J. L., Crosley, P., Hitt, M., Jenner, A. L., & Craig, M. (2023) · Cancer Biology & Therapy · doi:10.1080/15384047.2023.2283926 · Cited by 7
A Priori Identifiability of Target-Mediated Drug Disposition Models and Approximations
Eudy, R. J., Riggs, M. M., & Gastonguay, M. R. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9795-8 · Cited by 8
Wang, J., Giragossian, C., & Hansel, S. B. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.08.019 · Cited by 7
Timonen, J., Siccha, N., Bales, B., Lähdesmäki, H. J., & Vehtari, A. (2023) · Stat · doi:10.1002/sta4.614 · Cited by 7
Zhu, M., Wang, M., Li, Z., Wang, W., Su, X., & Jiao, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.673492 · Cited by 7
Mathematical Modeling of Remdesivir to Treat COVID-19: Can Dosing Be Optimized?
Conway, J. M., & Wiesch, P. A. Z. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081181 · Cited by 7
Tian, Z., Luo, H., Chu, Y., Liu, Y., Gao, S., Song, L., Yang, Z., & Liu, D. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01513-4 · Cited by 6
Desai, D. A., & Cristofoletti, R. (2025) · Clinical and Translational Science · doi:10.1111/cts.70356 · Cited by 6
Machine-learning-enabled modeling of pharmacokinetics and pharmacodynamics
Psarellis, Y. M., Pillai, N., Dhakal, S., & Mavroudis, P. D. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104645 · Cited by 6
Model‐Informed Optimal Dosing of Anti‐ CD47 Antibody Using Target‐Mediated Drug Disposition Model
Jeong, S., Lee, S., Kim, S. H., Kim, H. T., Yun, H., Chae, J., & Lee, S. (2025) · Clinical and Translational Science · doi:10.1111/cts.70321 · Cited by 6
Holmes, S., Jain, P., Rodríguez, K. B. G., Williams, J. L., Yu, Z., Cerda-Smith, C. G., Samuel, E. L. G., Campbell, J., Hakenjos, J. M., Monsivais, D., et al. (2024) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00464 · Cited by 6
A Pharmacokinetic Model Determination of Time Activity Curves in Radiopharmaceutical Therapy
Steiner, J. R., Nguyen, B., & Jafari, F. (2024) · Molecular Imaging · doi:10.1177/15353508241280015 · Cited by 6
A Framework for Quantitative Systems Pharmacology Model Execution
Sokolov, V. V., Peskov, K. V., & Helmlinger, G. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2024_738 · Cited by 7
Dynamics of target-mediated drug disposition: how a drug reaches its target
Peletier, L. A., & Gabrielsson, J. (2012) · Computational Geosciences · doi:10.1007/s10596-012-9312-4 · Cited by 6
Yoshiba, S., Jansen, M., Matsushima, N., Chen, S., & Mendell, J. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3011-0 · Cited by 6
Liu, H., Stresser, D. M., Michmerhuizen, M. J., Li, X., Othman, M. I. A., Reed, A. D., Schrimpf, M. R., Sydor, J. R., & Lee, A. J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.077511 · Cited by 7
D’Cunha, R., Widness, J. A., Yan, X., Schmidt, R. L., Veng‐Pedersen, P., & An, G. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1368 · Cited by 7
Peletier, L. A., Jansson‐Löfmark, R., & Gabrielsson, J. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105835 · Cited by 7
Shoji, S., Suzuki, A., Gaitonde, P., Cai, C., & Marshall, S. F. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15259 · Cited by 6
Foundations of Pharmacodynamic Systems Analysis
Jusko, W. J. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-44534-2_8 · Cited by 6
Self-citationYan, X., Ruixo, J. J. P., & Krzyżański, W. (2020) · The AAPS Journal · doi:10.1208/s12248-019-0410-2 · Cited by 6
Egbelowo, O. F., & Hoang, M. T. (2020) · Journal of Applied Mathematics and Computing · doi:10.1007/s12190-020-01452-2 · Cited by 6
Tilly, O. L., Gatault, P., Baron, C., Bejan‐Angoulvant, T., Büchler, M., Paintaud, G., & Ternant, D. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15235 · Cited by 6
Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT)
Varner, J. D. (2005) · Systems Biology · doi:10.1049/ip-syb:20050047 · Cited by 6
Parra-Guillen, Z. P., Janda, Á., Alzuguren, P., Berraondo, P., Hernández-Alcoceba, R., & Trocóniz, I. F. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9423-9 · Cited by 6
Ying, C. T., Wang, J., Lamm, R. J., & Kamei, D. T. (2013) · SLAS TECHNOLOGY · doi:10.1177/2211068212458265 · Cited by 6
Azzopardi, N., Longuet, H., Ternant, D., Thibault, G., Gouilleux‐Gruart, V., Lebranchu, Y., Büchler, M., Gatault, P., & Paintaud, G. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01053-7 · Cited by 5
Qiu, J., Yang, Y., Kong, J., Cao, Y., Liu, Y., Luo, H., & Cao, X. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.951176 · Cited by 6
Lobet, S., Paintaud, G., Azzopardi, N., Passot, C., Caulet, M., Chautard, R., Desvignes, C., Capitain, O., Tougeron, D., Lecomte, T., et al. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01270-2 · Cited by 5
Ji, Y., & Sy, S. K. B. (2024) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-024-04643-x · Cited by 5
Janus, A., Dumas, D., Douce, J. L., Marie, S., Pasculli, G., Bambury, P., Lemarchant, S., Kremer, P. H. C., & Godfrin, Y. (2024) · Neurology and Therapy · doi:10.1007/s40120-024-00691-w · Cited by 6
Pharmacokinetics of Therapeutic Proteins
Lu, Z., Sheng, J., & Zhang, W. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch10 · Cited by 6
Zhang, L., & Mager, D. E. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.024 · Cited by 6
Self-citationThibault, G., Paintaud, G., Sung, H. C., Lajoie, L., Louis, E. J., GETAID, T., Desvignes, C., Watier, H., Gouilleux‐Gruart, V., & Ternant, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116051 · Cited by 5
Algorithmic multiscale analysis for the FcRn mediated regulation of antibody PK in human
Patsatzis, D. G., Wu, S., Shah, D. K., & Goussis, D. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-09846-x · Cited by 5
Pressly, M. A., Peletier, L. A., Zheng, S., Sharma, V. D., Lien, Y. T., Wang, W., Zhou, H., & Schmidt, S. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12927 · Cited by 5
Pitsiu, M., Yalkinoglu, Ö., Farrell, C. B., Girard, P., Vazquez‐Mateo, C., & Papasouliotis, O. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12982 · Cited by 5
Wu, N., Katz, D. A., & An, G. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-023-01278-8 · Cited by 5
Pharmacokinetics and Pharmacodynamics of CD4-Anchoring Bi-Functional Fusion Inhibitor in Monkeys
Liu, X., Ou, Y. C., Zhang, J., Ahene, A. B., Clark, D., Hsieh, S., Cooper, M., & Ji, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1203-4 · Cited by 5
Zunino, C., Gualano, V., Zhou, H., Lukáčová, V., & Merdy, M. L. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070884 · Cited by 4
Suárez, N. D. C., Trame, M. N., Ramos, M., Dávalos, J. M., Bacallao-Méndez, R. A., Maceo-Sinabele, A. R., Sanjuan, V. M., Fernández, G. R., & Rodríguez‐Vera, L. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121147 · Cited by 4
Mager, D. E. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2025_746 · Cited by 4
Self-citationSelecting optimal drug-intervention in a pathway involving receptor tyrosine kinases (RTKs)
Benson, N., van der Graaf, P. H., & Peletier, L. A. (2016) · Nonlinear Analysis · doi:10.1016/j.na.2015.12.009 · Cited by 4
McLachlan, A. J., & Adiwidjaja, J. (2020) · Wiley eBooks · doi:10.1002/9781119564690.ch8 · Cited by 5
Ayyar, V. S., Jaiprasart, P., Geist, B. J., Devine, Z. H., Case, M., Hazra, A., Hsu, C., Chintala, M. S., & Wang, W. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15533 · Cited by 5
Ng, C. M., & Bauer, R. J. (2024) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-024-09936-5 · Cited by 4
Challenges in Pharmacology Modelling
Peletier, L. A., & Gabrielsson, J. (2014) · Journal of Dynamics and Differential Equations · doi:10.1007/s10884-014-9377-y · Cited by 4
Meneses‐Lorente, G., McIntyre, C., Hsu, J., Thomas, M., Jacob, W., Adessi, C., & Weisser, M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3328-3 · Cited by 4
Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab
Tiwari, A., Bhattacharya, I., Chan, P. L. S., & Harnisch, L. O. (2019) · Clinical and Translational Science · doi:10.1111/cts.12693 · Cited by 4
Alifrangis, L. H., Schoemaker, R. C., Skartved, N. J. Ø., Hald, R., Montagut, C. O., Kopetz, S., Tabernero, J. M., Kragh, M., & Wade, J. R. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09663-2 · Cited by 4
Oumghar, I. A., Barkaoui, A., Ghazi, A. E., & Chabrand, P. R. (2022) · Medical Engineering & Physics · doi:10.1016/j.medengphy.2023.103982 · Cited by 4
Yang, L., Zhu, X., Finlay, D. B., Green, H. M., Glass, M., & Duffull, S. B. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16158 · Cited by 4
Yuan, X., & An, G. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2438 · Cited by 4
Pharmacokinetics of erythropoiesis-stimulating agents
Doshi, S., Ruixo, J. J. P., Jang, G. R., & Chow, A. T. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_12 · Cited by 4
Receptor-Based Dosing Optimization of Erythropoietin in Juvenile Sheep after Phlebotomy
Rosebraugh, M., Widness, J. A., & Veng‐Pedersen, P. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.036855 · Cited by 4
Li, M., Qiang, W., Hu, L., Wang, L., & Cheng, Z. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.011 · Cited by 4
Li, M., Qiang, W., Wen, Z., Li, L., Wang, L., & Cheng, Z. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100716 · Cited by 4
Lowe, P. J., Kümmel, A., Vasalou, C., Matsushima, S., & Skerjanec, A. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse548 · Cited by 4
Cao, Y., & Jusko, W. J. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse547 · Cited by 5
Self-citationAntibody pharmacokinetics and pharmacodynamics
Joseph, P. B. (2005) · The Keio Journal of Medicine · Cited by 4
A Philosophical Framework for Integrating Systems Pharmacology Models Into Pharmacometrics
Duffull, S. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12148 · Cited by 3
Peletier, L. A., de Winter, W., & Vermeulen, A. (2012) · Discrete and Continuous Dynamical Systems - B · doi:10.3934/dcdsb.2012.17.2171 · Cited by 3
Singh, P., Tiwari, A., Abraham, A. K., & Zutshi, A. (2015) · CRC Press eBooks · doi:10.1201/b19023-7 · Cited by 3
Zhao, Q., Li, Q., Wang, Y., Li, L., Zhao, X., Ni, W., Fu, D., Yin, D., Feng, J., Hu, Z., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1647816 · Cited by 3
Yao, Q., Lee, Y., & Zhou, T. (2025) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-025-00780-4 · Cited by 5
Xu, M., & An, G. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00808-3 · Cited by 3
Li, R., Dere, E., Kwong, M., Fei, M., Dave, R. A., Masih, S., Wang, J., McNamara, E., Huang, H., Liang, W., et al. (2024) · The AAPS Journal · doi:10.1208/s12248-023-00881-8 · Cited by 3
Shu, C., Wang, Y., Feng, S., Yang, S., & Shen, K. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01512-5 · Cited by 3
Li, C., Santulli, A., Wart, S. V., Yang, L., Suryanarayan, K., Cook, S. F., Parot, X., Mager, D. E., & Gupta, N. (2025) · Clinical and Translational Science · doi:10.1111/cts.70296 · Cited by 3
Self-citationAffinity Affects the Functional Potency of Anti-GD2 Antibodies by Target-Mediated Drug Disposition
Troschke‐Meurer, S., Zumpe, M., Ahrenberg, P. M., Ebeling, T., Siebert, N., Grabarczyk, P., & Lode, H. N. (2025) · Cancers · doi:10.3390/cancers17152510 · Cited by 3
Takita, H., Darwich, A. S., Ahmad, A., & Rostami‐Hodjegan, A. (2020) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12557 · Cited by 3
Bai, S., Deng, R., Xiang, H., Gupta, M., Musib, L. C., Anand, B. S., & Lum, B. L. (2013) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-1-4614-9135-4_30 · Cited by 3
Lobet, S., Caulet, M., Paintaud, G., Azzopardi, N., Desvignes, C., Chautard, R., Borg, C., Capitain, O., Ferru, A., Bouché, O., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15983 · Cited by 3
Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial
Derbalah, A., Abdulla, T., Mendes, M. D. S., Wu, Q., Stader, F., Jamei, M., Gardner, I. B., & Sepp, A. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17050604 · Cited by 4
Mager, D. E. (2012) · Springer eBooks · doi:10.1007/978-1-4419-5955-3_11 · Cited by 3
Self-citationMarathe, A., Wart, S. V., & Mager, D. E. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9190-0 · Cited by 3
Self-citationBenson, N., van der Graaf, P. H., & Peletier, L. A. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.049 · Cited by 3
Peletier, L. A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1767-0_2 · Cited by 3
Khera, E., Kim, J., Stein, A. M., Ratanapanichkich, M., & Thurber, G. M. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001540 · Cited by 3
Target‐Driven Pharmacokinetics of Biotherapeutics
Huisinga, W., Fuhrmann, S., Fronton, L., & Krippendorff, B. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse549 · Cited by 3
Tumor Effect‐Site Pharmacokinetics: Mechanisms and Impact on Efficacy
Thurber, G. M. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse551 · Cited by 3
Tsanyan, M. E., Soloviev, S. K., Александрова, Е. Н., & Nasonov, E. L. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-eular.4734 · Cited by 3
Mallillin, M. C., Silva, D. A., Miller, N. A., Zhao, S., Salami, M., Löbenberg, R., & Davies, N. M. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070824 · Cited by 2
“…and trastuzumab illustrate the more typical situation in which TMDD measurably shapes PK at therapeutically relevant doses, particularly in patients with high tumor burden or shed antigen, requiring two-compartment or full TMDD models rather than empirical allometric extrapolation alone [47,50].”
InfluentialBerkhout, J., Fairman, D., van Noort, M., & van Steeg, T. J. (2024) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13234 · Cited by 2
Li, X., Wang, X., Zhu, S., Sun, F., Fu, Y., Ban, R., Tan, H. L. E., Yin, Z., Gao, Z., Xu, Z., et al. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103773 · Cited by 2
Straube, R. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70094 · Cited by 2
Ternant, D., Tilly, O. L., Cartron, G., Desvignes, C., Bensalem, A., Mulleman, D., Bejan‐Angoulvant, T., Gouilleux‐Gruart, V., & Paintaud, G. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01549-6 · Cited by 2
Nasiri, F., & Hooshmand, M. (2024) · Bioinformatics Advances · doi:10.1093/bioadv/vbaf192 · Cited by 5
On the coupling between a basic FcRn mechanism and target-mediated disposition of antibodies
Kátai, C. B., Berns, M. M. M., & Elassaiss‐Schaap, J. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-10006-7 · Cited by 2
A Tutorial on the Development of a Physiologically Inspired PKRO Model for Monoclonal Antibodies
Kapitanov, G. I., Flowers, D. A., Marcantonio, D. H., Lezon, T. R., Apgar, J. F., & Hua, F. (2025) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.70160 · Cited by 2
Modeling ADME/Tox for Drug Discovery in the Age of Data
Aniceto, N., Freitas, A. A., & Ghafourian, T. (2025) · Springer handbooks · doi:10.1007/978-3-031-81728-1_18 · Cited by 2
Pharmacokinetic modeling to optimize development and therapeutic potential of mAb-based therapies
Fan, X., Chen, C., Zhang, L., Cao, K., & Yan, X. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115850 · Cited by 3
Nolain, P., Fugger, M., Hellinghus, B. T., Hilgendorf, I., Højen, J. F., Libby, P., Liuzzo, G., Matter, C. M., Tuttle, K. R., & Ridker, P. M. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120742 · Cited by 2
Onyango, I. G., Woolf, N., Green, J., Stinchcomb, M., & Matveyeva, M. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104350 · Cited by 2
Pharmaco-microdynamics (PMD): Redefining dose, exposure, and control for living drug carriers
Abdullah, M., Jayadevan, K., Therayil, A., Kumaraguruparan, N., Kavyasree, P. K. V., Dilna, P., & Faiza, A. (2026) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2026.06.002 · Cited by 2
Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
Brekkan, A., Jönsson, S., Karlsson, M. O., & Hooker, A. C. (2018) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-018-9594-9 · Cited by 3
Byun, J. H., Park, A., & Jung, I. H. (2020) · Journal of Applied Analysis & Computation · doi:10.11948/20190232 · Cited by 2
Wang, J., Chen, T., Ruszaj, D. M., Mager, D. E., & Straubinger, R. M. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.019 · Cited by 2
Self-citation
Metadata
- Authors
- Mager, D. E., & Jusko, W. J.
- Affiliations
- University at Buffalo, State University of New York (US)
- Venue
- Journal of Pharmacokinetics and Pharmacodynamics
- Published
- 2001-12
- Volume
- 28
- Issue
- 6
- Pages
- 507-532
- ISSN
- 1567-567X (ISSN-L)
- 1573-8744
- OpenAlex
- W28215347
- Cited by
- 605
- References
- 40
- Citations by year
- 2026: 40 · 2025: 27 · 2024: 30 · 2023: 32 · 2022: 31 · 2021: 31 · 2020: 40 · 2019: 37 · 2018: 28 · 2017: 31 · 2016: 32 · 2015: 41 · 2014: 31 · 2013: 36 · 2012: 32
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Journal of Pharmacokinetics and Pharmacodynamics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM 57980, R01GM057980)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- target-mediated drug disposition, nonlinear pharmacokinetics, receptor-mediated endocytosis, pharmacokinetic modeling, dose-dependent clearance, drug elimination, bosentan, interferon beta-1a, enzyme inhibitors, receptor antagonists
- MeSH terms
- Bosentan, Dose-Response Relationship, Drug, Drug Evaluation, Preclinical, Fluorenes, Humans, Hydantoins, Male, Models, Chemical, Pharmacokinetics, Sulfonamides, Drug Delivery Systems, Interferon-beta, Nonlinear Dynamics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.